1
|
Dong SC, Sha HH, Xu XY, Hu TM, Lou R, Li H, Wu JZ, Dan C, Feng J. Glutathione S-transferase π: a potential role in antitumor therapy. Drug Des Devel Ther 2018; 12:3535-3547. [PMID: 30425455 PMCID: PMC6204874 DOI: 10.2147/dddt.s169833] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Glutathione S-transferase π (GSTπ) is a Phase II metabolic enzyme that is an important facilitator of cellular detoxification. Traditional dogma asserts that GSTπ functions to catalyze glutathione (GSH)-substrate conjunction to preserve the macromolecule upon exposure to oxidative stress, thus defending cells against various toxic compounds. Over the past 20 years, abnormal GSTπ expression has been linked to the occurrence of tumor resistance to chemotherapy drugs, demonstrating that this enzyme possesses functions beyond metabolism. This revelation reveals exciting possibilities in the realm of drug discovery, as GSTπ inhibitors and its prodrugs offer a feasible strategy in designing anticancer drugs with the primary purpose of reversing tumor resistance. In connection with the authors' current research, we provide a review on the biological function of GSTπ and current developments in GSTπ-targeting drugs, as well as the prospects of future strategies.
Collapse
Affiliation(s)
- Shu-Chen Dong
- Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210009, China, ;
| | - Huan-Huan Sha
- Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210009, China, ;
| | - Xiao-Yue Xu
- Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210009, China, ;
| | - Tian-Mu Hu
- Department of Biological Science, Purdue University, West Lafayette, IN, USA
| | - Rui Lou
- Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210009, China, ;
| | - Huizi Li
- Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210009, China, ;
| | - Jian-Zhong Wu
- Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210009, China, ;
| | - Chen Dan
- Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210009, China, ;
| | - Jifeng Feng
- Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210009, China, ;
| |
Collapse
|
2
|
Jiang H, Zhang X, Chen J, Zhang L, Xiong J, Zhong L, Yu F, Qian J, Yu L, Wang X, Shi G, Deng J, Xu N. A study of weekly docetaxel and carboplatin as first-line chemotherapy for advanced non-small cell lung cancer. J Thorac Dis 2014; 6:79-85. [PMID: 24605220 DOI: 10.3978/j.issn.2072-1439.2014.01.24] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2013] [Accepted: 01/22/2014] [Indexed: 12/29/2022]
Abstract
BACKGROUND Weekly docetaxel demonstrated similar efficacy but better tolerability than standard triweekly docetaxel, and carboplatin was less nephrotoxic, neurotoxic and emetogenic than cisplatin. This study aimed to evaluate the efficacy and safety of weekly docetaxel with carboplatin as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC). METHODS Forty-three Chinese patients have been included. Patients were administered docetaxel at a dose of 35 mg/m(2) on days 1, 8, 15 and carboplatin at an area under the curve (AUC) 5 on day 1 every 28-day cycle (maximum six cycles). RESULTS Of the 43 eligible patients, the assessed overall response rate (RR) was 30.2% with 30.2% partial response (PR) in 13 patients, 48.8% stable disease (SD) in 21 patients and 20.9% progressive disease (PD) in 9 patients. The estimated median progression free survival and median overall survival (OS) time were respectively, 120 days (95% CI: 80-160 days) and 340 days (95% CI: 224-456 days) with the patients surviving of 46.5% (95% CI: 31.6-61.4%) at one year and 20.0% (95% CI: 7.1-33.3%) at two years. The major grade 3/4 hematological toxicities were included leucocytopenia in 6 patients (13.9%) and neutropenia in 8 patients (18.6%). One patient (2.3%) suffered grade 1 febrile neutropenia. All grade of the nonhematological toxicities, such as nausea, vomiting, alopecia and fatigue held the proportion of 48.8% (grade 3/4 4.6%), 27.9%, 55.8% and 53.5% (grade 3/4 9.3%), respectively. CONCLUSIONS The combination of weekly docetaxel and carboplatin showed feasible efficacy with acceptable hematologic toxicities for advanced lung cancer.
Collapse
Affiliation(s)
- Haiping Jiang
- 1 Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China ; 2 Department of Oncology, The First Affiliated Hospital, Nanchang University, Nanchang 330006, China ; 3 Beijing Merck Pharmaceutical Consulting Ltd, Beijing 100022, China
| | - Xiaochen Zhang
- 1 Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China ; 2 Department of Oncology, The First Affiliated Hospital, Nanchang University, Nanchang 330006, China ; 3 Beijing Merck Pharmaceutical Consulting Ltd, Beijing 100022, China
| | - Jing Chen
- 1 Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China ; 2 Department of Oncology, The First Affiliated Hospital, Nanchang University, Nanchang 330006, China ; 3 Beijing Merck Pharmaceutical Consulting Ltd, Beijing 100022, China
| | - Ling Zhang
- 1 Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China ; 2 Department of Oncology, The First Affiliated Hospital, Nanchang University, Nanchang 330006, China ; 3 Beijing Merck Pharmaceutical Consulting Ltd, Beijing 100022, China
| | - Jianping Xiong
- 1 Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China ; 2 Department of Oncology, The First Affiliated Hospital, Nanchang University, Nanchang 330006, China ; 3 Beijing Merck Pharmaceutical Consulting Ltd, Beijing 100022, China
| | - Lin Zhong
- 1 Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China ; 2 Department of Oncology, The First Affiliated Hospital, Nanchang University, Nanchang 330006, China ; 3 Beijing Merck Pharmaceutical Consulting Ltd, Beijing 100022, China
| | - Feng Yu
- 1 Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China ; 2 Department of Oncology, The First Affiliated Hospital, Nanchang University, Nanchang 330006, China ; 3 Beijing Merck Pharmaceutical Consulting Ltd, Beijing 100022, China
| | - Jiong Qian
- 1 Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China ; 2 Department of Oncology, The First Affiliated Hospital, Nanchang University, Nanchang 330006, China ; 3 Beijing Merck Pharmaceutical Consulting Ltd, Beijing 100022, China
| | - Lanfang Yu
- 1 Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China ; 2 Department of Oncology, The First Affiliated Hospital, Nanchang University, Nanchang 330006, China ; 3 Beijing Merck Pharmaceutical Consulting Ltd, Beijing 100022, China
| | - Xiaoting Wang
- 1 Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China ; 2 Department of Oncology, The First Affiliated Hospital, Nanchang University, Nanchang 330006, China ; 3 Beijing Merck Pharmaceutical Consulting Ltd, Beijing 100022, China
| | - Genming Shi
- 1 Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China ; 2 Department of Oncology, The First Affiliated Hospital, Nanchang University, Nanchang 330006, China ; 3 Beijing Merck Pharmaceutical Consulting Ltd, Beijing 100022, China
| | - Jing Deng
- 1 Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China ; 2 Department of Oncology, The First Affiliated Hospital, Nanchang University, Nanchang 330006, China ; 3 Beijing Merck Pharmaceutical Consulting Ltd, Beijing 100022, China
| | - Nong Xu
- 1 Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China ; 2 Department of Oncology, The First Affiliated Hospital, Nanchang University, Nanchang 330006, China ; 3 Beijing Merck Pharmaceutical Consulting Ltd, Beijing 100022, China
| |
Collapse
|
3
|
Chen X, Ren B, Chen M, Liu MX, Ren W, Wang QX, Zhang LX, Yan GY. ASDCD: antifungal synergistic drug combination database. PLoS One 2014; 9:e86499. [PMID: 24475134 PMCID: PMC3901703 DOI: 10.1371/journal.pone.0086499] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2013] [Accepted: 12/09/2013] [Indexed: 12/12/2022] Open
Abstract
Finding effective drugs to treat fungal infections has important clinical significance based on high mortality rates, especially in an immunodeficient population. Traditional antifungal drugs with single targets have been reported to cause serious side effects and drug resistance. Nowadays, however, drug combinations, particularly with respect to synergistic interaction, have attracted the attention of researchers. In fact, synergistic drug combinations could simultaneously affect multiple subpopulations, targets, and diseases. Therefore, a strategy that employs synergistic antifungal drug combinations could eliminate the limitations noted above and offer the opportunity to explore this emerging bioactive chemical space. However, it is first necessary to build a powerful database in order to facilitate the analysis of drug combinations. To address this gap in our knowledge, we have built the first Antifungal Synergistic Drug Combination Database (ASDCD), including previously published synergistic antifungal drug combinations, chemical structures, targets, target-related signaling pathways, indications, and other pertinent data. Its current version includes 210 antifungal synergistic drug combinations and 1225 drug-target interactions, involving 105 individual drugs from more than 12,000 references. ASDCD is freely available at http://ASDCD.amss.ac.cn.
Collapse
Affiliation(s)
- Xing Chen
- National Centre for Mathematics and Interdisciplinary Sciences, Chinese Academy of Sciences, Beijing, P. R. China
- Academy of Mathematics and Systems Science, Chinese Academy of Sciences, Beijing, P. R. China
| | - Biao Ren
- University of Chinese Academy of Sciences, Beijing, P. R. China
- South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou, P. R. China
| | - Ming Chen
- Chinese Academy of Sciences Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, P. R. China
| | - Ming-Xi Liu
- Academy of Mathematics and Systems Science, Chinese Academy of Sciences, Beijing, P. R. China
- University of Chinese Academy of Sciences, Beijing, P. R. China
| | - Wei Ren
- Academy of Mathematics and Systems Science, Chinese Academy of Sciences, Beijing, P. R. China
| | - Quan-Xin Wang
- School of Life Science, University of Science and Technology of China, Hefei, P.R. China
| | - Li-Xin Zhang
- South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou, P. R. China
- Chinese Academy of Sciences Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, P. R. China
- * E-mail: (LXZ); (GYY)
| | - Gui-Ying Yan
- National Centre for Mathematics and Interdisciplinary Sciences, Chinese Academy of Sciences, Beijing, P. R. China
- Academy of Mathematics and Systems Science, Chinese Academy of Sciences, Beijing, P. R. China
- * E-mail: (LXZ); (GYY)
| |
Collapse
|
5
|
Hesketh PJ, Chansky K, Wozniak AJ, Hirsch FR, Spreafico A, Moon J, Mack PC, Marchello BT, Franklin WA, Crowley JJ, Gandara DR. Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2. J Thorac Oncol 2008; 3:1026-31. [PMID: 18758306 PMCID: PMC3523698 DOI: 10.1097/jto.0b013e318183aa1f] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
PURPOSE This phase II study (S0341) evaluated the efficacy and tolerability of single-agent erlotinib in unselected chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) of 2. Exploratory analyses of a number of biomarkers relating to epidermal growth factor receptor pathway activation were also performed. PATIENTS AND METHODS Patients with stage IIIB (pleural effusion) or stage IV NSCLC with a PS of 2 and no prior chemotherapy or biologic treatment for NSCLC received erlotinib 150 mg daily. RESULTS A total of 81 patients entered the study; 76 were assessable. One complete and 5 partial responses were noted for an overall response rate of 8% (95% CI 3%-16%). Stable disease (SD) was seen in 26 patients (34%) resulting in a disease control rate (DCR = CR/PR/SD) of 42%. Progression free and median survival were 2.1 months (95% CI 1.5-3.1) and 5 months (95% CI 3.6-7.2), respectively. One-year survival was 24% (95% CI 15%-34%). Although treatment was generally well tolerated, grade 3 to 4 toxicity was reported in 30 patients (40%), including fatigue (16%), rash (9%), diarrhea (7%), and anorexia (7%). There was one possible treatment related death (pneumonitis). CONCLUSIONS In chemotherapy-naive patients with advanced NSCLC and a PS of 2, single agent erlotinib resulted in an acceptable but significant level of treatment-related side effects. With an overall DCR of 42% and median survival of 5 months, results are comparable to those achieved with chemotherapy in this population. Development of an epidermal growth factor receptor-directed biomarker selection strategy may optimize use of erlotinib in PS 2 patients.
Collapse
Affiliation(s)
- Paul J. Hesketh
- Caritas St. Elizabeth’s Medical Center of Boston, Boston, MA
| | - Kari Chansky
- Southwest Oncology Group Statistical Center, Seattle, WA
| | | | | | | | - James Moon
- Southwest Oncology Group Statistical Center, Seattle, WA
| | | | | | | | | | | |
Collapse
|